HTG Molecular Diagnostics Announces the Institute of Oncology Research Has Adopted the HTG EdgeSeq Technology in its Genomics Facility
HTG’s extraction-free, targeted next-generation sequencing technology adopted to support the IOR’s research and clinical trials in hematological cancers and solid tumors
“We are honored to have this prestigious group select our technology to support its research and clinical trials,” said TJ Johnson, Chief Executive Officer of HTG Molecular. “The IOR is a terrific partner and we look forward to helping it discover the next-generation of cancer therapies.”
HTG is focused on NGS-based molecular profiling. The proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries and ultimately to identify treatment options. HTG’s mission is to empower precision medicine at the local level.
Safe Harbor Statement:
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the scope of the IOR’s future use of HTG’s EdgeSeq technology at its genomics facility and the anticipated benefits or outcomes from such use. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based upon management’s current expectations, are subject to known and unknown risks, and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation, the risk that the IOR may choose to use alterative molecular sequencing technology in the future and risks inherent to cancer research and clinical trials. These and other factors are described in greater detail in our filings with the Securities and Exchange Commission, including without limitation our Quarterly Report on Form 10-Q for the quarter ended June 30, 2018. All forward-looking statements contained in this press release speak only as of the date on which they were made, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Phone: (617) 535-7742
Source: HTG Molecular Diagnostics, Inc.